NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/20/2026
Back to search
Official data from USPTO
NXERA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000098404554Class
1, 5, 35, 42, 44
Filing
98404554
Registration
8106109
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
04/03/2026
Trademark type
Combined
Nice classes
1, 5, 35, 42, 44
Filing date
02/13/2024
Registration date
01/20/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/20/2026
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
TOKYO, JP
Examiner
DUBIN, DAVID I
Law office
L70
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "NXERA" featured in black positioned within a yellow rectangle design that is connected to a smaller yellow rectangle design positioned to the right of the larger rectangle design that features a black flag design within the smaller rectangle design. The stylized wording and design, as illustrated in the mark, are positioned on top of a transparent rectangular background. The color white represents background, outlining, shading, and transparent areas and is not claimed as a feature of the mark.
Holders and representatives
Holders
NXERA PHARMA CO., LTD
Sosei Group Corporation
Representatives
Eric Lamb Frost Brown Todd LLP
Technical classification
Nice Classes
Class 1Class 5Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical products and proteins both for use in the manufacture of industrial chemicals and biological pharmaceutical products; chemical products being industrial chemicals and protein in raw material form for scientific and medical research being research of chemical and biological pharmaceutical products; chemical products being industrial chemicals and proteins for industrial use in the field of diagnostic useexcept medical or veterinary uses; protein for industrial use and G-protein coupled receptors being protein for industrial use for manufacturing pharmaceutical products; protein for industrial use and G-protein-coupled receptors being protein for industrial use for the research of pharmaceutical products; industrial chemicals and protein for industrial use for use in the fields of chemical and biological drug discoverylead identification and diagnostics; protein for industrial use and G-protein-coupled receptors being protein for industrial use for drug discovery purposes; industrial chemicals and biologicals in the nature of protein for industrial usetransmembrane proteins and G-proteins both being protein for industrial useG-protein-coupled receptors being protein for industrial usefragments thereof being sequences of amino acids in the nature of amino acidsother than for medical or veterinary purposesfor use in the fields of chemical and biological drug discoverylead identification and diagnostics; protein for industrial use in the nature of transmembrane proteins and G-proteins both being protein for industrial useG-protein-coupled receptors being protein for industrial usefragments thereof being sequences of amino acids in the nature of amino acidsother than for medical or veterinary purposesfor use in the fields of pharmaceutical research and drug discovery purposes
Class 5
Pharmaceutical preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicines for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological products for medical purposesmedicinal preparations being G-protein-coupled receptors for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the fields of chemical and biological drug discoverylead identificationdiagnostics and therapeutic purposes; biological and chemical products for medical useprotein supplements; biological and chemical products for medical usemedicinal preparation being G-protein-coupled receptors for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical usemedicinal preparation being transmembrane proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical usemedicinal preparation being G-proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical useantibodies for medical purposes and synthetic peptides and parts thereof being synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; chemical reagents for medical use and protein supplements for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of medical diagnostics; biological products being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of chemical and biological drug discoveryin the field of lead identification and diagnostics; biological products being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for therapeutic purposes; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of developing chemical and biological pharmaceutical products; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of identifying lead chemical and biological products; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for diagnostic use; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for therapeutic use; protein supplements and medicinal preparations being G-protein-coupled receptorsboth for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of drug discovery purposes; biological reagents for medical purposes and medicinal preparations being small chemical entities for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being G-protein-coupled receptors for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being transmembrane proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being G-proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; antibodies for medical purposes and synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; protein supplements for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; antibodies for medical purposes and synthetic peptides for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders in the field of medical diagnostics
Class 35
Business managementbusiness organization consultingbusiness administrationall provided in the fields of chemical productsbiological productspharmaceuticalsdesign and development of drugsdrug discovery; Business managementbusiness organization consultingbusiness administrationall provided in the field of pharmaceutical and biopharmaceutical research and developmentfield of technologies related to proteins and G-protein-coupled receptors; wholesale and retail store services featuring pharmaceuticalsbiological products and chemical and biological preparations
Class 42
Drug discovery services and pharmaceutical discovery services being pharmaceutical research services; Biotechnology research; pharmaceutical research services; chemical and medical testing in the nature of testing of chemicals; researchdevelopmentadviceconsultancy and information servicesdesign and testing of new products for others; research and development services in the field of pharmaceutical preparations being pharmaceuticals and biopharmaceuticals and field of pharmaceutical preparations being technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in the fields of chemical and biological drug discovery and development; pharmaceutical research services and pharmaceutical products development for identifying lead chemical compounds; examination and research services being pharmaceutical research services in the field of medicinal and synthetic chemistry; scientific research and development services in the fields of creation of libraries and collections of biologicalschemicals and compounds; researchcreationdevelopmentscientific research and development in the field of chemical and biological drug targets for screening purposes; researchanalysis and examinationscientific research and development in the field of identification of compounds through automated screening processes; scientific research and development services in the field of chemical and biological pharmaceutical development; medical research laboratory services; provision of informationadvisory services and consultancy in connection with all of the aforesaid services
Class 44
Pharmaceutical compounding services; pharmaceutical advice and medical and pharmaceutical consultation; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; medical and pharmaceutical consultation in the fields of researchcreationdevelopment and provision of chemical and biological drug targets for medical screening purposes; all of the aforesaid services provided in the field of drug discovery and field of use of G-protein- coupled receptors in the design and development of pharmaceutical products
Publications
History of USPTO decisions and trademark events.
30 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/20/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/02/2025
PUBO
PUBLISHED FOR OPPOSITION
12/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/26/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/31/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/31/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/31/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/31/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/31/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/23/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/23/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/23/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/25/2025
GNFR
FINAL REFUSAL E-MAILED
06/25/2025
CNFR
FINAL REFUSAL WRITTEN
06/25/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/28/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/12/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/02/2024
GNRT
NON-FINAL ACTION E-MAILED
12/02/2024
CNRT
NON-FINAL ACTION WRITTEN
12/02/2024
DOCK
ASSIGNED TO EXAMINER
07/16/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/04/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/25/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/25/2024
NWAP
NEW APPLICATION ENTERED
02/13/2024
Continuous trademark protection
Get notified about every new filing that threatens NXERA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.